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Phe Clinical Issue
ith recent advances in catheter technology and adjunctive
harmacotherapy, percutaneous coronary intervention (PCI)
as achieved high procedural success rates and is a widely
sed means of myocardial revascularization among patients
ith coronary artery disease. Outcomes after PCI vary
epending on patient selection, angiographic complexity,
perator skill, and institutional care practices. Periproce-
ural myocardial infarction (MI) is detected in up to 30% of
atients undergoing PCI, depending on the marker tested,
opulation studied, and threshold for diagnosis based upon
he degree of marker elevation (1). In clinical trials of
CI-related therapies, periprocedural MI is commonly
djudicated as an outcome measure and has been shown to
e significantly associated with increased long-term mortal-
ty (2–5). However, there is no clearly defined threshold at
hich this increase in risk and definition of “myocardial
nfarction” converge, nor is there consensus on what treat-
ent should be rendered when elevated markers are de-
rom the *Duke Clinical Research Institute, Durham, North Carolina; †University ofp
exas Health Science Center, Houston, Texas; and the ‡Northern California Kaiser
ermanente, Oakland, California.ected after a procedure (6). As such, expert panels have
aried in their recommendations. Although some recom-
end routine cardiac marker testing after PCI (1), others
ecommend measurements driven by evidence of symptom-
tic ischemia or procedural complications (7,8).
Recent quality improvement initiatives have led to the
evelopment of both regional and national databases scru-
inizing PCI practice and outcome variations (9–11).
hereas periprocedural MI has been suggested as a metric
or assessing the quality of PCI care, in light of the
forementioned differences in opinion regarding the role of
eriprocedural marker testing, the viability of periprocedural
I as a quality metric should be assessed. Studies to date
xamining the incidence of periprocedural MI have largely
een composed of single-center registries or post hoc
linical trial database analyses in which post-procedure
ardiac marker measurements are mandated by study pro-
ocol. With the American College of Cardiology National
ardiovascular Database CathPCI Registry (ACC-
CDR), we investigated contemporary patterns of post-
CI cardiac marker testing in a large national database,
atient predictors of marker testing, and variability among
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May 27, 2008:2068–74 Periprocedural MI as a Quality Metric for PCIospitals in the frequency of marker measurement and
eriprocedural MI detection.
ata From the ACC-NCDR
he ACC-NCDR is a large, ongoing, national registry of
iagnostic cardiac catheterization and PCI in the U.S. and,
s such, offers a unique opportunity to examine contempo-
ary patterns of post-PCI cardiac marker testing. Patient
nd hospital characteristics were collected prospectively via a
tandardized set of data elements and definitions (12).
Between January 1, 2004, and March 30, 2007, data from
08,481 consecutive patients undergoing PCI in the U.S.
ere entered into the ACC-NCDR database. Patients who
resented with acute coronary syndrome (n  458,658) or
ith pre-procedure creatine kinase (CK)-MB or troponin
evels greater than the upper limit of normal (ULN) (n 
6,428) were excluded, owing to the inability to determine
hether post-PCI marker testing was performed as a result
f the presenting ACS event and likely overlap of positive
ardiac markers from the pre- to post-PCI time periods.
he final study population consisted of 213,395 patients
ho underwent elective PCI at 463 hospitals with no
eported evidence of myocardial necrosis before the PCI
rocedure.
atterns of Cardiac Marker Testing
cross all hospitals, a median of 7% of patients undergoing
CI had post-procedure CK-MB levels measured. As
hown in Figure 1, most hospitals did not routinely measure
K-MB levels after elective PCI; 298 of 463 hospitals
64.4%) measured post-procedure CK-MB levels in 20%
f patients who underwent PCI. On the other end of the
pectrum, 59 of 463 hospitals (12.7%) performed post-
igure 1 Distribution of Hospitals
y the Frequency of Post-Procedure Cardiac Marker Testing
K  creatine kinase; PCI  percutaneous coronary intervention.frocedure marker testing more
outinely in 70% of patients un-
ergoing PCI. Hospitals that rou-
inely measured post-procedure
ardiac markers (defined as those
hat measured markers in 70%
f patients undergoing PCI) had
igher diagnostic catheterization
nd PCI volumes/year (Table 1).
A total of 52,746 patients
24.7% of the total PCI popula-
ion) had CK-MB assessment af-
er PCI. Among the 181,990 pa-
ients treated at 404 hospitals that
o not routinely measure post-
CI markers, there were very few
ifferences in baseline demographic or clinical characteris-
ics between patients with and without CK-MB testing
Table 2). However, patients with post-PCI CK-MB mea-
urement had higher-risk angiographic characteristics such
s multivessel disease, bifurcation or type C lesions, and
esions requiring the use of debulking devices. Although
eriprocedural ischemia was not captured in the data col-
ection form, patients with measured markers had longer
rocedural times and higher rates of procedural complica-
ions such as vessel dissection or acute vessel closure (Table
).
Multivariable logistic regression was used to determine
actors independently associated with cardiac marker testing
n patients who underwent PCI at hospitals that do not
outinely assess post-procedure markers. Among these in-
ependent patient and hospital variables (Table 4), the most
ignificant factor associated with testing was the presence of
periprocedural complication.
ssociation of Marker Testing With
eriprocedural MI Detection and Outcomes
mong the 52,746 patients with measured CK-MB levels,
2,728 (24%) had new CK-MB elevations greater than the
LN after procedure. Of these patients, 8,351 (16%) had
eak CK-MB levels between 1 and 3  ULN and 4,377
8%) had peak CK-MB levels 3  ULN—a threshold
ften used to define periprocedural MI in consensus recom-
endations (6). Among patients with peak CK-MB levels
3  ULN, only 14.9% had reported periprocedural compli-
ations such as acute closure, perforation, or dissection.
Patients undergoing elective PCI at hospitals that rou-
inely measured post-procedure markers had a trend toward
ower in-hospital mortality compared with those treated at
ospitals that do not perform routine marker testing: odds
atio 0.74, 95% confidence interval 0.53 to 1.02 after
djustment for independent predictors of mortality derived
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
CABG  coronary artery
bypass grafting
CK  creatine kinase
MI  myocardial infarction
NCDR  National
Cardiovascular Database
Registry
PCI  percutaneous coronary
intervention
ULN  upper limit of normalrom a validated mortality risk model for patients undergo-
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Periprocedural MI as a Quality Metric for PCI May 27, 2008:2068–74ng PCI (unpublished model from the ACC-NCDR data-
ase, c-index  0.93, including age, body mass index,
iabetes, prior heart failure, prior PCI, prior cerebrovascular
r peripheral vascular disease, renal dysfunction, cardiogenic
hock, ejection fraction, lesion severity, lesion complexity
ACC/American Heart Association (AHA)/Society of
ardiovascular Angiography and Interventions (SCAI) le-
ion classification type], and pre-procedure Thrombolysis In
yocardial Infarction [TIMI] flow). Patients treated at
ospitals that routinely performed post-procedure CK-MB
esting were also more likely to be discharged on guideline-
ecommended secondary prevention therapies.
As shown in Figure 2, periprocedural MI detection
defined as peak CK-MB levels 3  ULN) correlated
Table 1 Hospital Characteristics
Hospitals W
>70% Marker T
(n  59)
Number of inpatient beds* 400 (254, 5
Academic hospital (%)† 61.0
Diagnostic catheter volume/yr* 2,000 (1,046,
PCI volume/yr* 785 (296, 1,
Surgical backup (%) 86.4
Hospital region (%)
West 15.3
Northeast 20.3
Midwest 35.6
South 25.4
Hospital location (%)
Urban 50.8
Suburban 23.7
Rural 25.4
*Presented as median (25th, 75th percentile). †Academic affiliation refl
PCI  percutaneous coronary intervention.
able 2 Baseline Patient Characteristics Among 181,990
atients Treated at 404 Hospitals That Measured Post-PCI
K-MB Levels in <70% of Patients
Patients With
Post-PCI
Marker Testing
(n  25,214)
Patients Without
Post-PCI
Marker Testing
(n  156,776)
emographic (%)
Age (yrs)* 66 (57, 74) 66 (57, 74)
Female 32.7 33.3
Caucasian 85.8 87.7
linical history (%)
Hypertension 80.2 79.4
Diabetes mellitus 35.1 34.7
Dyslipidemia 80.0 78.9
Prior MI 28.2 29.9
Prior PCI 40.5 41.5
Prior CABG 19.7 20.0
Prior CHF 11.0 11.0
Peripheral vascular disease 13.8 13.0
Renal insufficiency 5.2 5.3
total of 31,405 patients from 59 hospitals that routinely measured post-percutaneous coronary
ntervention (PCI) creatine kinase (CK)-MB levels (in70% of all patients undergoing PCI) were not
ncluded in this table. *Presented as median (25th, 75th percentile).a
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure, MI  myocardial
nfarction.ith the frequency of CK-MB measurement (p  0.0001).
ospitals that more routinely measured markers had signif-
cantly higher rates of periprocedural MI detection (4.8% vs.
.6%, p  0.0001). However, the association was reversed
hen the denominator was limited to only those patients
ith measured CK-MB levels (n  52,746). Hospitals that
ested less frequently had higher rates of periprocedural MI
etection (11.4% vs. 5.4%, p  0.0001).
iscussion
his report from the ACC-NCDR shows that post-
rocedure cardiac markers are assessed in only one-quarter
f patients after elective PCI, with wide variations in the
attern of marker surveillance across hospitals in the U.S.
ospitals that routinely performed marker testing had
igher rates of periprocedural MI detection despite a trend
oward lower mortality and greater adherence to recom-
ended medications that suggest better overall quality of
are for PCI patients at these hospitals. Therefore, in the
bsence of routine cardiac marker surveillance after PCI, the
se of periprocedural MI as a quality metric for PCI will be
isleading.
urrent Patterns of
ost-Procedure Cardiac Marker Testing
n the ACC/AHA/SCAI PCI guidelines, post-procedure
K-MB measurement was designated as a class IB recom-
endation for patients with suspected ischemia during PCI,
hereas routine marker measurement for all patients under-
oing PCI was given a class IIC recommendation (8,13).
his report shows that most clinicians are following guide-
ine recommendations and primarily performing testing in
atients with higher-risk lesions or procedural complica-
ions. As a result, cardiac markers are assessed infrequently
Hospitals With
<70% Marker Testing
(n  404) p Value
348 (249, 500) 0.07
54.5 0.34
1,459 (900, 2,313) 0.02
568 (329, 882) 0.04
85.9 0.91
21.8 0.13
10.4
37.4
29.0
53.2 0.37
28.7
18.1
ing in Council of Teaching Hospitals.ith
esting
89)
3,300)
193)fter PCI; yet the frequency of marker measurement corre-
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May 27, 2008:2068–74 Periprocedural MI as a Quality Metric for PCIated directly with the likelihood of periprocedural MI
etection. Although clinically apparent procedural compli-
ations such as distal embolization, side branch occlusion, or
ntimal dissection contribute to periprocedural myocardial
njury (14–17), the overall incidence of such complications
as low and the majority of patients with CK-MB elevation
ad no reported periprocedural complication. These obser-
ations raise the concern that in the absence of complica-
ions meeting the threshold for suspected ischemia during
CI that might instigate post-procedure marker testing,
ospitals that do not routinely perform marker testing
ight significantly underestimate the true incidence of
eriprocedural MI.
Notably, 8,166 patients (4% of the overall population)
ad troponin-only measurements after PCI. Troponin has
ecome the preferred cardiac biomarker, owing to its high
ensitivity and specificity for myocardial damage (6).
mong patients undergoing PCI, the magnitude of post-
rocedural troponin elevation correlates directly with the
xtent of myocardial injury (6,18). Yet, although troponin is
ore sensitive than CK-MB in detecting smaller amounts
f periprocedural myonecrosis, the prognostic implications
Table 3 Angiographic and Procedural Character
Treated at 404 Hospitals That Measured Post-P
P
Disease burden (%)
Ejection fraction*
Multivessel disease
Worst lesion characteristic (%)
Lesion location
Left main
Proximal LAD
Proximal RCA/mid LAD/proximal LCx
Other
Pre-procedure TIMI flow grade 0 to 1
High-risk (type C) lesion†
Lesion length 20 mm
Bifurcation lesion
Device used (%)
Any stent
Drug-eluting stent
Debulking device‡
Procedural characteristics (%)
Fluoroscopy time (min)*
Contrast volume (ml)*
Lesion success (%)§
Any procedural complication (%)
Dissection
Acute vessel closure
Perforation
No reflow
A total of 31,405 patients from 59 hospitals that routinely measure
included in this table. *Presented as median (25th, 75th percentile). †Pe
classification scheme (29): high-risk (type C) lesion defined as length 2
90°, total occlusions3 months old and/or bridging collaterals, inabilit
‡Debulking device includes any atherectomy, thrombectomy, or extrac
Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 with 25% r
Procedural complication defined as any coronary dissection, perforation
LAD  left anterior descending coronary artery; LCx  left circumflf troponin elevation after PCI are less certain (19–22). In Cstudy by Cavallini et al. (20), troponin elevation was
etected in 44% of patients undergoing PCI (vs. 16%
K-MB elevation) but, unlike CK-MB, did not predict
-year mortality (odds ratio 1.2, 95% confidence interval 0.9
o 1.7). Similarly, a study by Miller et al. (23) showed that the
ise in troponin post-procedure was not predictive of long-term
utcomes. As such, troponin elevations were not incorpo-
ated into the definition of periprocedural MI in this report.
mplications of Detecting Periprocedural Myocardial Injury
outine marker measurement after PCI has been contro-
ersial, largely owing to its uncertain utility in the absence of
linically apparent ischemia during PCI, particularly in
egard to therapeutic decision-making after PCI when an
symptomatic periprocedural MI is detected. Among pa-
ients with uncomplicated PCI, CK-MB elevation has been
ssociated with discrete regions of delayed hyperenhance-
ent within the target vessel perfusion territory on mag-
etic resonance imaging as well as more diffuse plaque
urden and thrombus-rich lesions (24–26). As such, prac-
ice guidelines recommend that patients with periprocedural
Among 181,990 Patients
-MB Levels in <70% of Patients
With Post-PCI
ker Testing
 25,214)
Patients Without Post-PCI
Marker Testing
(n  156,776)
(50, 61) 57 (50, 60)
55.5 52.5
2.2 2.0
17.7 17.6
39.7 38.7
40.3 41.8
12.2 13.7
39.4 35.2
39.9 37.9
14.6 12.1
90.5 91.3
80.7 82.1
5.4 4.8
(7.4, 20.2) 11.1 (6.9, 18.3)
(140, 270) 190 (135, 250)
95.7 95.1
4.9 3.1
3.9 2.6
1.4 0.6
0.5 0.3
0.8 0.4
CI CK-MB levels (in 70% of all patients undergoing PCI) were not
can College of Cardiology/American Heart Association (ACC/AHA) lesion
cessive tortuosity of proximal segment, extremely angulated segments
tect major side branches, or degenerated vein grafts with a friable lesion.
heters or cutting balloons. §Lesion success defined as post-procedure
stenosis if lesion stented or 50% residual stenosis if no stent used.
ow, or acute closure during the procedure.
y; RCA  right coronary artery; other abbreviations as in Table 2.istics
CI CK
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Periprocedural MI as a Quality Metric for PCI May 27, 2008:2068–74tandard MI patient with initiation of appropriate secondary
revention measures before discharge (6,8,13). This report
howed that patients who underwent routine post-
rocedure CK-MB testing were more likely to be dis-
harged on aspirin, clopidogrel, beta-blocker drugs, and
tatin drugs, so routine surveillance of post-PCI cardiac
arkers seems to correlate with better quality of overall
ospital care for patients undergoing PCI.
On an institutional level, routine post-procedure marker
easurement could potentially stimulate more rigorous
ssessment of PCI quality and influence PCI practices (27).
eriprocedural MI rates higher than national standards
hould prompt institutional review of the patient case-mix
or PCI procedures, decision-making regarding the choice
f percutaneous versus surgical revascularization for individ-
al patients, operator technique, device selection, and the
se of adjunctive pharmacotherapies during PCI procedures
hat affect periprocedural complications.
hould Periprocedural MI Be Used as a Quality Metric?
eriprocedural MI, an end point frequently used in clinical
rials, has been suggested as a quality metric for PCI care
28). However, on the basis of these results, observational
atabases, in contrast to clinical trials, cannot provide an
ccurate assessment of the frequency of periprocedural MI,
wing to wide variations in the measurement of post-
rocedure cardiac markers. Although several states have
nstituted quality improvement data registries that mandate
Table 4 Factors Associated With Post-Procedur
Treated at 404 Hospitals That Measured Post-P
Variable
Adjusted
Odds Rati
Patient factors
Previous MI 0.91
Dyslipidemia 1.07
Previous CABG 0.94
Heart failure on admission 1.07
Angiographic factors
Procedural complication* 1.56
High-risk/type C lesion† 1.17
Multivessel disease burden 1.15
Bifurcation lesion 1.19
Pre-procedure TIMI flow grade 0 to 1 1.07
Post-procedure TIMI flow grade 0 to 1 1.16
Stent use 0.86
Debulking device use‡ 1.08
Hospital factors
Midwest hospital location 0.73
Teaching hospital 0.83
Hospital beds (per 100 increase) 1.03
Northeast hospital location 1.21
A total of 31,405 patients from 59 hospitals that routinely measure
included in this table. Other nonsignificant variables included in the
intervention, lesion location, and hospital region. *Procedural complica
during the procedure. †Per ACC/AHA lesion classification scheme (29): h
segment, extremely angulated segments 90°, total occlusions 3 mo
degenerated vein grafts with a friable lesion. ‡Debulking device includes
Abbreviations as in Tables 2 and 3.ost-procedural marker assessment (10,11), very few hospi- uals nationally perform systematic post-PCI marker surveil-
ance. Because most periprocedural MIs are clinically silent,
outine marker measurement after PCI is necessary to make
dequate comparisons of quality of care and procedural
utcomes across hospitals.
Hospitals that routinely measure post-procedure CK-MB
evels likely represent those that have a strong interest in
uality improvement, as suggested by the trend toward
ower adjusted in-hospital mortality and greater use of
ppropriate discharge medications. However, the principle
f “the more you look, the more you find” is demonstrated
ere. Hospitals that routinely screen for periprocedural MI
ight in fact be penalized for practicing a “quality process”
y demonstrating worse outcomes (higher rates of peripro-
edural MI) when benchmarked against hospitals that
easure post-procedure markers less frequently. Thus, at
his time, periprocedural MI cannot be a quality metric for
CI care unless routine post-procedure marker measure-
ent is implemented universally.
Several limitations of the data were present. First, among
atients with post-procedural marker measurement, the
ncidence of periprocedural MI might be underestimated if
he patient was discharged before enough time elapsed for
ost-PCI markers to reach a true peak. Second, detailed
nformation regarding periprocedural ischemic symptoms
nd electrocardiographic changes was not collected in this
egistry. Finally, although we adjusted for a broad range of
linical and hospital variables in the mortality analysis,
rdiac Marker Testing Among 181,990 Patients
-MB Levels in <70% of Patients
95%
Confidence
Interval Chi-Square p Value
0.88–0.94 36.4 0.001
1.04–1.11 15.6 0.001
0.91–0.98 9.4 0.002
1.02–1.12 6.8 0.009
1.47–1.67 180.3 0.001
1.14–1.21 118.8 0.001
1.12–1.19 96.2 0.001
1.14–1.24 76.6 0.001
1.05–1.08 54.3 0.001
1.11–1.21 50.0 0.001
0.82–0.90 37.8 0.001
1.01–1.14 5.5 0.02
0.71–0.76 354.3 0.001
0.80–0.85 155.0 0.001
1.03–1.04 76.1 0.001
1.15–1.26 67.6 0.001
CI CK-MB levels (in 70% of all patients undergoing PCI) were not
l are age, gender, diabetes, dyslipidemia, renal failure, multivessel
fined as any coronary dissection, perforation, no reflow, or acute closure
(type C) lesion defined as length 2 cm, excessive tortuosity of proximal
and/or bridging collaterals, inability to protect major side branches, or
erectomy, thrombectomy, or extraction catheters or cutting balloons.e Ca
CI CK
o
d post-P
mode
tion de
igh-risk
nths old
any athnmeasured confounders might have influenced the results.
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May 27, 2008:2068–74 Periprocedural MI as a Quality Metric for PCIonclusions
lthough periprocedural MI has been advocated as a quality
ndicator of PCI care, current data show that the majority of
ospitals do not systematically assess cardiac markers after
lective PCI; thus, the incidence of periprocedural MI
ight be significantly underestimated in current clinical
ractice. Therefore, the use of periprocedural MI as a
uality metric for PCI procedures will remain misleading
ntil efforts to standardize marker measurement practices
re successful.
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